Paul Hastings Advises BioMarin Pharmaceutical Inc. in Follow-On Public Offering

June 05, 2012

San Francisco, CA (June 5, 2012) - Paul Hastings LLP, a leading global law firm, announced today that the firm advised BioMarin Pharmaceutical Inc., a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten offering of 6,500,000 shares of common stock. In connection with launching the offering BioMarin estimated the offering would raise gross proceeds of approximately $249 million before costs.

BofA Merrill Lynch and Barclays acted as the underwriters in the offering.

Securities & Capital Markets partner Thomas Pollock led the Paul Hastings team, which also included corporate associates Samantha Eldredge and Aliza Cohen.

Paul Hastings LLP is a leading global law firm with offices in Asia, Europe, and the United States. We provide innovative legal solutions to financial institutions and Fortune 500 companies. Please visit www.paulhastings.com for more information.